Investigational drug · Phase 2
Tifeglipron
Also called: RO7795081, CT-996, RG6652
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type 2 Diabetes Mellitus, Obesity or Overweight.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
2
Any phase or sponsor naming "Tifeglipron"
First trial start
2025
Jul 29, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Tifeglipron", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 2 Diabetes Mellitus
- Obesity or Overweight
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Tifeglipron" as an intervention, largest first.
- A Study Evaluating the Effect of Daily Oral Tifeglipron (RO7795081) in Participants With Obesity or Overweight With at Least One Weight-Related ComorbidityPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07081958 · 352 participants · Start Jul 29, 2025 · Primary completion Apr 28, 2026
Drug: Tifeglipron; Placebo · For: Obesity or Overweight
Sites: Anniston, Alabama; Lake Forest, California; Rancho Cucamonga, California · 36 sites in all
- A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 DiabetesPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07112872 · 330 participants (planned) · Start Aug 19, 2025 · Primary completion Feb 5, 2028
Drug: Tifeglipron; Semaglutide and 1 more · For: Type 2 Diabetes Mellitus
Sites: Tucson, Arizona; Lake Forest, California; Rancho Cucamonga, California · 51 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A comparative analysis of the safety and tolerability of oral small-molecule versus injectable peptide GLP-1 receptor agonists.
Habib MA, Sulieman AK, Albarq Z, et al. · Endocrine 2026
Also in development for Type 2 Diabetes Mellitus
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- ElecoglipronPhase 39 trials
AstraZeneca · Type 2 Diabetes Mellitus, Obesity, Overweight
- LenbelintideAZD6234Phase 39 trials
AstraZeneca · Obesity or Overweight, Obesity, Overweight
- ASC30 A1ASC30Phase 35 trials
Ascletis Pharma (China) Co., Limited · Chronic Weight Management, Obesity, Overweight
- SHR-3167Phase 35 trials
Jiangsu HengRui Medicine Co., Ltd. · Diabetes Mellitus, Type 2, Type 2 Diabetes, Type 2 Diabetes Mellitus
- HTD1801Berberine UrsodeoxycholatePhase 34 trials
Shenzhen HighTide Biopharmaceutical Ltd. · T2DM (Type 2 Diabetes Mellitus), Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes
- DA-302168SPhase 33 trials
Chendu DIAO Pharmaceutical Group CO., LTD. · Overweight and Obesity, Type 2 Diabetes Mellitus
- TG103Phase 33 trials
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Type 2 Diabetes Mellitus, Overweight or Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.